News

BioSpace13h
Novavax Approval Process a Potential ‘Harbinger’ of Threat to FDA Integrity: Former Regulators
Writing in JAMA, four former governmental officials warn that the Trump administration’s involvement in delaying the approval ...
FDA probes deaths of boys taking Sarepta Duchenne drug
The FDA said yesterday that it is investigating the deaths from liver failure of two non-ambulatory boys with Duchenne ...
Investor's Business Daily on MSN23h
Why Viking Therapeutics, 67% Off Its Recent Highs, Could Still Have An Edge In Obesity
Viking TherapeuticsVKTX stock remains under pressure, but analysts said Wednesday the company's strategy for its Phase 3 obesity studies could pay off big time against bigger rival Eli LillyLLY.The ...
Did The FDA Make A Mistake? Sarepta's Elevidys Approval Under Scrutiny
FDA is investigating Sarepta's Elevidys after two deaths from liver failure in non-ambulatory DMD patients, raising safety ...
Asianet Newsable on MSN23h
Sarepta Stock Slumps After FDA Opens Probe Into Patient Death, Analyst Sounds Alarm
H.C. Wainwright reiterated a ‘Sell’ rating on Sarepta on Wednesday with a $10 price target. The firm views the FDA as a ...